Victory Capital Management Inc. Has $89,000 Stake in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Victory Capital Management Inc. lifted its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 111.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,097 shares of the biopharmaceutical company’s stock after buying an additional 18,532 shares during the period. Victory Capital Management Inc.’s holdings in Puma Biotechnology were worth $89,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Los Angeles Capital Management LLC acquired a new position in Puma Biotechnology during the 3rd quarter worth approximately $627,000. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Puma Biotechnology by 72.7% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 8,000 shares in the last quarter. SG Americas Securities LLC acquired a new position in Puma Biotechnology during the third quarter worth $34,000. Frazier Life Sciences Management L.P. grew its position in Puma Biotechnology by 8.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after purchasing an additional 246,264 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Puma Biotechnology in the 2nd quarter valued at $58,000. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Stock Performance

NASDAQ PBYI opened at $3.39 on Monday. The firm’s fifty day moving average price is $2.84 and its two-hundred day moving average price is $3.11. Puma Biotechnology, Inc. has a 1 year low of $2.22 and a 1 year high of $7.73. The firm has a market capitalization of $166.42 million, a P/E ratio of 7.06 and a beta of 1.09. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter last year, the company posted $0.12 earnings per share. As a group, research analysts anticipate that Puma Biotechnology, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

PBYI has been the subject of several analyst reports. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a research report on Wednesday, November 20th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.